Twój koszyk jest obecnie pusty!
39% of people over the age of 18 are overweight
Changes in eating habits and increased availability of high-calorie foods have made overweight and obesity one of the most serious health issues of our era. In 2016, the World Health Organization (WHO) estimated that 39% of people over the age of 18 are overweight, and the global prevalence of obesity has nearly tripled from 1975 to 2016. Furthermore, the WHO report stated that nearly 2.8 million deaths annually are consequences of overweight and obesity-related diseases, including hypertension, dyslipidemia, insulin resistance, ischemic stroke, type 2 diabetes, and the development of cancer [WHO 2016].
Gut microbiota may contribute to obesity
Obesity and metabolic syndrome are influenced by many physiological factors that, besides genetic and environmental factors, are strongly linked to diet, which affects the gut microbiota. Importantly, in recent years, there has been much evidence showing that gut microbiota may contribute to obesity [Castaner et al. 2018; Bell 2017; Festi et al. 2014]. Despite ongoing uncertainties in this area, we can already state that microbiota influences obesity through mechanisms such as carbohydrate fermentation, lipogenesis, excess energy storage, hormones, and neurotransmitters, some of which are known for controlling food intake and regulating energy balance [Shahid et al. 2018].
Probiotics as a solution
The above-mentioned facts suggest that manipulating the gut microbiota through diet or other means may have beneficial effects by restoring intestinal functional integrity and reversing dysbiosis, which is characteristic of obesity. Such an approach is highly desirable as it would lower treatment costs and significantly reduce the risk of harm to patients compared to more drastic and invasive interventions currently used in obesity treatment, such as bariatric surgery. In this regard, probiotics seem to be a very good solution, as they are already commonly considered an intervention factor in manipulating the gut microbiota composition.
Studies show weight and BMI reduction
Scientific studies show that several probiotics, used alone or in synbiotic mixtures, can counteract obesity through mechanisms specific to each species and strain, for example, by modulating the gut microbiota, reducing insulin resistance, and increasing satiety [Abenavoli et al. 2019]. For example, Lactobacillus spp. species, including L. Casei, L. gasseri, L. rhamnosus, L. plantarum, and Bifidobacterium spp., such as B. infantis, B. longum, and B. breve, have been successfully used in well-known animal models of obesity due to their low pathogenicity and low antibiotic resistance [Cerdó et al. 2019]. Probiotic therapies involving these species led to less weight gain and reduced fat accumulation. Among human studies, pediatric research stands out. For example, supplementation with Lactobacillus rhamnosus GG in the treatment of children for six months reduced weight gain in this subgroup (age range 1-4 years) [Luoto et al. 2010]. Additionally, the use of multi-strain probiotic compositions containing L. rhamnosus, L. acidophilus, L. delbrueckii subsp. Bulgaricus, L. paracasei, L. plantarum, or B. longum showed beneficial effects on BMI, liver fat, insulin resistance, and GLP-1 levels in children treated for obesity [Alisi et al. 2014; Famouri et al. 2017]. Positive effects were also noted in adults. Scientists who administered bacteria strains from Lactobacillus and Bifidobacterium genera documented significant reductions in weight, BMI, waist circumference, and fat mass [Higashikawa et al. 2016; Kim et al. 2018; Minami et al. 2018].
EkoSynbiotyk – Effective Probiotic in the Fight Against Overweight
In conclusion, it is worth adding that EkoSynbiotyk contains probiotic bacterial strains, which, as indicated by the studies above, have a supportive effect in the treatment of obesity, including Lactobacillus plantarum, L. acidophilus, and Bifidobacterium longum. Importantly, the strains found in EkoSynbiotyk come from natural fermentation, which enhances their probiotic effect.
Visit our store
References:
WHO. Overweight and Obesity. Available online: read more
Castaner, O.; Goday, A.; Park, Y.M.; Lee, S.H.; Magkos, F.; Shiow, S.T.E.; Schröder, H. The Gut Microbiome Profile in Obesity: A Systematic Review. Int. J. Endocrinol. 2018, 2018, 4095789. read more
Bell, C.G. The Epigenomic Analysis of Human Obesity. Obesity 2017, 25, 1471–1481. read more
Festi, D.; Schiumerini, R.; Eusebi, L.H.; Marasco, G.; Taddia, M.; Colecchia, A. Gut microbiota and metabolic syndrome. World J. Gastroenterol. 2014, 20, 16079–16094. read more
Shahid, S.U.; Irfan, U. The gut microbiota and its potential role in obesity. Future Microbiol. 2018, 13, 589–603. read more
Abenavoli, L.; Scarpellini, E.; Colica, C.; Boccuto, L.; Salehi, B.; Sharifi-Rad, J.; Aiello, V.; Romano, B.; De Lorenzo, A.; Izzo, A.A.; Capasso, R. Gut Microbiota and Obesity: A Role for Probiotics. Nutrients 2019, 11, 2690. read more
Cerdó, T.; García-Santos, J.A.; Bermúdez, M.G.; Campoy, C. The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. Nutrients 2019, 11, 635. read more
Luoto, R.; Kalliomäki, M.; Laitinen, K.; Isolauri, E. The impact of perinatal probiotic intervention on the development of overweight and obesity: Follow-up study from birth to 10 years. Int. J. Obes. 2010, 34, 1531–1537. [Google Scholar] [CrossRef]
Alisi, A.; Bedogni, G.; Baviera, G.; Giorgio, V.; Porro, E.; Paris, C.; Giammaria, P.; Reali, L.; Anania, F.; Nobili, V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharm. Ther. 2014, 39, 1276–1285. read more
Famouri, F.; Shariat, Z.; Hashemipour, M.; Keikha, M.; Kelishadi, R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J. Pediatr. Gastroenterol. Nutr. 2017, 64, 413–417. read more
Higashikawa, F.; Noda, M.; Awaya, T.; Danshiitsoodol, N.; Matoba, Y.; Kumagai, T.; Sugiyama, M. Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: A randomized, double-blind, placebo-controlled clinical trial. Eur. J. Clin. Nutr. 2016, 70, 582–587. read more
Kim, J.; Yun, J.M.; Kim, M.K.; Kwon, O.; Cho, B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Med. Food 2018, 21, 454–461. read more
Minami, J.; Iwabuchi, N.; Tanaka, M.; Yamauchi, K.; Xiao, J.-Z.; Abe, F.; Sakane, N. Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: A randomized, double-blind, placebo-controlled trial. Biosci. Microbiota Food Health 2018, 37, 67–75. read more
WHO estimated that 39% of people over 18 years of age are overweight, and the global prevalence of obesity has nearly tripled since 1975.